Immunovant and Roivant jump as new drug shapes up to become blockbusterProactive Investors • 09/26/23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsGlobeNewsWire • 09/26/23
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023GlobeNewsWire • 09/26/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 09/20/23
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023GlobeNewsWire • 08/10/23
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023GlobeNewsWire • 05/22/23
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022GlobeNewsWire • 02/03/23
These Were the Five Best and Worst Performing Small-cap Stocks in October 202224/7 Wall Street • 11/08/22
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14thGlobeNewsWire • 11/07/22
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022GlobeNewsWire • 11/04/22